BRAF targets in melanoma. Biological mechanisms, resistance, and drug discovery. Cancer drug discovery and development. Volume 82. Ed. Ryan J. Sullivan. Springer (2015)
Although clinical activity cannot be directly compared across trials, vemurafenib and dabrafenib provide fairly equivalent benefit for patients with BRAFV600E mutant melanoma [12, 19]. Median PFS and response rates were comparable. Side effect profiles were also similar with phototoxicity and elevated liver function tests occurring more frequently with vemurafenib and pyrexia more commonly observed with dabrafenib. A suggestion of fewer cutaneous SCCs was also considered with dabrafenib in the phase III trial but this was called into question in a subsequent trial . See Sect 5.5 for the discussion of BRAF inhibitor therapy in brain metastases and in alternative BRAF mutations (non-V600E).
[contact-form-7 id=»5168″ title=»Контактная форма 1″]